Eli Lilly fell well short of Wall Street’s first-quarter expectations, and the drugmaker chopped the top end of its earnings forecast due to lower demand for COVID-19 treatments
Slipping COVID-19 treatment demand hits Eli Lilly forecast
© The Crystal Eyes